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Abstract
We report the metabolism of the recently introduced α,α-difluoroethyl thioether motif to explore further its potential as a substitu-
ent for bioactives discovery chemistry. Incubation of two aryl–SCF2CH3 ethers with the model yeast organism Cunninghamella
elegans, indicates that the sulfur of the thioether is rapidly converted to the corresponding sulfoxide, and then significantly more
slowly to the sulfone. When the substrate was (p-OMe)PhSCF2CH3, then the resultant (demethylated) phenol sulfoxide had an
enantiomeric excess of 60%, and when the substrate was the β-substituted-SCF2CH3 naphthalene, then the enantiomeric excess of
the resultant sulfoxide was 54%. There was no evidence of defluorination, unlike the corresponding oxygen ether
(p-OMe)PhOCF2CH3, which was converted to the (demethylated) phenol acetate ester during C. elegans incubation. We conclude
that the aryl–S–CF2CH3 motif is metabolised in a similar manner to aryl–SCF3, a motif that is being widely explored in discovery
chemistry. It is however, significantly less lipophilic than aryl-SCF3 which may offer a practical advantage in tuning overall phar-
macokinetic profiles of molecules in development.
Introduction
Fluorine and fluorinated substituents are routinely used to
modify the properties of lead compounds in medicinal chem-
istry and in bioactive discovery programmes [1,2]. To this end,
aryl–F and aryl–CF3 are the most common modifications found
in compounds registered in the patent literature [3], substitu-
ents which are typically introduced to stop metabolism of aryl
rings [4]. Other fluorinated motifs are gaining in importance
too, such as aryl–OCF3 and aryl–SCF3 ethers, although these
substituents can significantly raise lipophilicity (log P) [5,6].
There are relatively few bioactives on the market in this class,
some of which are illustrated in Figure 1, however, it is notice-
able that there is an increasingly active methodology focus
describing new ways to introduce -OCF3 and -SCF3, and it can
be anticipated that the number of bioactives of this class will
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Figure 1: Structures of trifluoromethyl sulfonyl ether bioactives.
Figure 2: Comparison of log P values of comparative aryl thioether
motifs [18].
increase [7]. The -OCF3 substituent is not directly metabolised,
however, the sulphur associated with the -SCF3 group is
susceptible to in vivo oxidation.
Tiflorex, an appetite suppressant, toltrazuril, a coccidiostat used
as an additive to poultry feed, and SKA-19, an anticonvulsant
as shown in Figure 1, are three such compounds that are of
commercial significance [8-10]. Metabolism studies in both of
these cases show that the major metabolites are their corre-
spond ing  su l fox ides  (Ar–S(O)CF 3 )  and  su l fones
(Ar–S(O)2CF3) [8,9]. Indeed, in the case of the insecticide
fipronil it is actually the sulfoxide (Ar–S(O)CF3) that is
marketed as the active component [11,12]. The increase in
lipophilicity associated with these substituents is not always
desirable. In this regard, partially fluorinated alkyl substituents
become an interesting alternative, as the fluorines polarise the
adjacent hydrogens and lipophilicity reduces relative to the
perfluoro substituents [13-15]. In this context we recently intro-
duced aryl α,α-difluoroethyl thioethers such as 1 as a motif of
this class [16-18]. Log P assessments of PhSCF2CH3 (1) indi-
cate that it is more polar than the PhSCF3 (2) and also the ali-
phatic PhSCH2CH3 ether 3 as shown in Figure 2. Therefore,
there is potential for the inclusion of this motif in candidate
molecules without a significant increase in log P.
Having explored synthetic routes and log P evaluations, we now
report our initial studies on the metabolism of the ArSCF2CH3
substituent. In this context, the potential for P450 oxidation at
sulphur is the most obvious metabolic vulnerability, and also
hydrolytic susceptibility to release fluoride. We chose to
explore the metabolism of aryl α,α-difluoroethyl thioethers 4
and 5 by Cunninghamella elegans as representative compounds
of this class. This fungus is rich in cytochrome P450 activity
and has been used as a model organism in which to mimic
phase one mammalian metabolism of xenobiotics [19-21].
Results and Discussion
The two aryl α,α-difluoroethyl thioethers 4 and 5 in Figure 3
were selected for C. elegans incubations rather than 1, as they
are less volatile, to avoid evaporation losses during extended
incubations and work-up. Cultures of C. elegans were grown in
Saboraud dextrose medium and incubated on an orbital shaker
at 28 °C for 72 hours. New metabolites could be conveniently
observed by extracting aliquots of the media into diethyl ether
and dichloromethane (DCM) and then carrying out HPLC
analyses.
Figure 3: α,α-Difluoroethyl thioether substrates for metabolism
studies.
Incubation of thioether 4 with C. elegans led to the identifica-
tion of three metabolites 6–8 as illustrated in Scheme 1. These
were isolated by semi-preparative HPLC. Two of these (6 and
7) displayed an AB system in the 19F NMR spectrum consis-
tent with non-equivalence of the fluorines, immediately indica-
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Scheme 1: Fluorometabolites 6–8 isolated after incubation of 4 with C. elegans. Ratios are the average of three incubations. The structure of 7 was
confirmed by X-ray structure analysis.
Scheme 2: Putative pathways for (α,α-difluoroethyl)(4-methoxyphenyl)sulfane (4) metabolism.
tive of sulfoxide formation. Isolation and subsequent 1H and
19F NMR analyses as well as high-resolution mass spectrome-
try secured the identity of these metabolites as sulfoxides 6 and
7 and sulfone 8. The structure of sulfoxide 7 was also con-
firmed by X-ray structure analysis. The incubation of 4 in
C. elegans, and then HPLC purification, was repeated three
times all with very similar results. These incubations showed
full conversion into the metabolites, and no starting thioether 4
was observed by NMR or HPLC.
Sulfone 8 was a relatively minor metabolite, at only 10% of
sulfoxide 6. A chiral HPLC (IC column, solvent: 5%
isopropanol in hexane; 1 mL/min) enantiomeric assay was con-
ducted for sulfoxide 6 and the outcome compared with a
racemic sample of 6, prepared by chemical oxidation of
thioether 4 [22]. Although we could not determine the absolute
stereochemistry of the predominant enantiomer, it was clear
from the assay that there was a significant enantiomeric ratio
(4:1) of 6 which translates to a 60% enantiomeric excess (ee,
see Supporting Information File 1). We note that there have
been chemical methods developed for the synthesis of enantio-
merically enriched aryl fluoroalkyl sulfoxides, however, this
appears to be the first enzymatic approach [23-25].
Although the fungus was able to both oxidise the sulfur and
demethylate the para-methoxy group of 4, there was no obvious
presence of novel metabolites which did not contain fluorine.
This points to a hydrolytically stable motif over the period of
the incubation. In an effort to establish the sequence of events
through which these metabolites are generated, each was
separately re-incubated with C. elegans to establish if they
could be further metabolised. Product profiles were again deter-
mined by HPLC analysis and relationships are summarised in
Scheme 2.
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Scheme 3: C. elegans incubation of 5. Ratios are the average of three incubations.
Scheme 4: Incubation (four times) of oxygen ether 14 with C. elegans, gave 4-acetoxyphenol (15) as the major metabolite. On one occasion 16 was
tentatively observed as a minor metabolite.
Incubation of racemic sulfoxide 6 led to a similar outcome to
that for 4 with the formation of phenol sulfoxide 7 and phenol
sulfone 8 suggesting that sulfoxide 6 is the first formed metabo-
lite with demethylation following subsequently at a slower rate.
The experiments on the re-incubation of phenols 7 and 8 failed
to lead to any further metabolism, where they appeared to be
stable metabolites, certainly for the period (72 h) of the incuba-
tion. We were unable to observe a transformation from sulf-
oxide 6 to sulfone 9 in these re-incubation experiments. It may
be that there is a barrier to uptake of the phenols into the fungal
cells and that they are actively exuded when generated within
the cell. As a final experiment sulfone 9, which was not ob-
served as a metabolite, was prepared by mCPBA oxidation of
thioether 4. This sulfone was then incubated with C. elegans
and it gave rise to demethylated phenol 8 as the sole metabolite,
consistent with an active demethylation capacity of this fungus.
Non-oxidised phenol 10 was also not observed in this study.
Overall this suggests that sulfoxidation is very active and
outcompetes demethylation, however, that demethylation is sig-
nificantly more active that the second oxidation of sulfoxides to
sulfones.
Incubation of naphthalene 5 with C. elegans, generated three
new metabolites 11–13 which arose by oxidations at sulphur
and hydroxylations of the naphthalene ring, as summarised in
Scheme 3. These metabolites were isolated by reversed-phase
HPLC and characterised by 1H and 19F NMR and mass spec-
trometry. This identified sulfoxides 11 and 12 as the major
metabolites and a trace amount of a minor sulfone which had
the general structure 13 as determined by mass spectrometry.
Naphthalene 5 was fully converted. Again, initial sulfoxidation
dominates, but the second oxidation of the sulfoxide to a
sulfone appears to be a slower process, and is outcompeted by
aryl hydroxylation reactions. The experiment was conducted
three times under similar conditions, all with very similar
outcomes.
In order to explore the stereoselectivity of this sulfoxidation,
sulfoxide 11 isolated from the C. elegans incubation was
analysed by chiral HPLC (IC column, solvent: 5% isopropanol
in hexane; 1 mL/min). This was compared to a racemic refer-
ence sample of 11 prepared by chemical oxidation of thioether
5. The resultant enantiomeric ratio for 11 was determined to be
3.3:1, which translates to a 54% ee (absolute stereochemistry
not determined). Again, the sulfoxidation shows a significant
stereochemical bias.
The stability of the aryl thioethers can be contrasted with the
hydrolytic lability of the analogous oxygen ethers. By way of
example α,α-difluoroethyl ether 14 [18] was incubated with
cultures of C. elegans under the standardised conditions, as
illustrated in Scheme 4. 19F NMR of the extract indicated a
trace of residual starting material with one major metabolite
which was isolated by HPLC. This was identified as
4-acetoxyphenol (15). Aryl ether demethylation remains highly
active, but unlike the α,α-difluoroethyl thioethers 4 and 5, the
oxygen ether is vulnerable to hydrolytic fluoride release.
Oxygen ether 14 is particularly labile, and the incubation
proceeds to full conversion to generate acetate ester 15.
The incubation of 14 was carried out four times, all affording
consistent results and generating 15 as the clearly identifiable
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product. However, in one experiment minor traces of a fluori-
nated metabolite was observed. Although a full characterisation
was not possible due to the low levels recovered, 1H and
19F NMR for this metabolite showed an intact -OCF2CH3
motif, as well as a para-substitution pattern, which suggested
the identity of 4-(1,1-difluoroethoxy)phenol (16).
Conclusion
In conclusion, we have explored Cunninghamella elegans
fungal metabolism of the α ,α-difluoroethyl thioether
(Ar–SCF2CH3) motif, which we introduced recently as a more
polar alternative to RSCF3. It emerges to have a similar metabo-
lism to ArSCF3 in that it progresses to the sulfoxide and then
the sulfone, although in this study the initial oxidation to the
sulfoxide was significantly more rapid than the second oxida-
tion to the sulfone. The first oxidation gave enantiomerically
enriched sulfoxides (Ar–S(O)CF2CH3) in the 54–60% ee range.
This could arise by the action of more than one P450 enzyme.
There was no evidence of defluorination, or hydroxylation at
the terminal -CH3 group. The corresponding oxygen ether 14
was susceptible to hydrolytic defluorination to generate an
acetate ester. The α,α-difluoroethyl thioether (Ar–SCF2CH3)
motif can be readily prepared from thiols and emerges as a
potentially attractive substituent for consideration by medicinal
chemists and for other areas of bioactives discovery research, to
complement the widely used ROCF3 and RSCF3 groups and
there is a clear similarity to the ‘polar lipophilic’ groups
ROCF2H, and RSCF2H [26].
Experimental
Microorganism growth
Cunninghamella elegans DSM1908 was grown on Saboraud
dextrose agar gel plates for 120 h at 28 °C, from previous
stocks. The plates were stored at 4 °C for a maximum of
4 months. Liquid cultures were prepared by inoculation from
mycelium from the plates, into Saboraud dextrose broth
(50 mL), and grown on an incubator shaker for 72 h at 28 °C
and 180 rpm.
Synthesis of substrates
Thioethers 4 and 5 and oxygen ether 14 were prepared as previ-
ously described [18]. Compounds 6, 8 and11 were prepared as
described below.
1-(α,α-Difluoroethyl)sulfinyl)-4-methoxybenzene (6)
(1,1-Difluoroethyl)(4-methoxyphenyl)sulfane (4, 5 mg,
0.025 mmol) was added to a round bottom flask with a stirring
bar and dissolved in a mixture of DCM (3 mL) and methanol
(0.3 mL). The solution was stirred at room temperature until
homogenisation (5 min). AlCl3 (1.8 mg, 0.012 mmol) was
added, and the solution stirred for 5 min, prior to the addition of
[bis(acetoxy)iodo]benzene (BAIB, 7.3 mg, 0.025 mmol). The
reaction was left to stir overnight. After 16 h, the solvents were
evaporated under reduced pressure. The remaining mixture
showed the formation of 6 with 66% conversion from the
starting material 4. Further purification was achieved by
reversed-phase HPLC in a Phenomenex Luna SP column, with
60:40 AcCN/water (supplemented with 0.05% TFA) at a flow
rate of 1 mL/min. The product 6 was isolated at tR = 24 min,
which was consistent with the metabolic experiment’s data.
1H NMR (500 MHz, chloroform-d) δH 7.65 (d, J = 8.9 Hz, 2H),
7.08 (d, J = 8.9 Hz, 2H), 3.89 (s, 1H), 1.81 (t, J = 18.4 Hz, 1H);
19F NMR (471 MHz, chloroform-d) δF −93.4 (d, J = 225.1 Hz),
−97.1 (d, J = 225.1 Hz).
1–(α,α-Difluoroethyl)sulfonyl)-4-hydroxybenzene (8)
(1,1-Difluoroethyl)(4-methoxyphenyl)sulfane (4, 5 mg,
0.025 mmol) was added to a round bottom flask containing a
stirring bar, and dissolved in CH2Cl2 (1.5 mL). mCPBA was
added to the solution (21 mg, 0.122 mmol), and the mixture was
stirred at rt overnight. The reaction was quenched by addition of
a saturated solution of NaHCO3. The aqueous phase was
extracted into CH2Cl2 (3 × 3 mL). The combined organic
phases were combined, dried over Na2SO4, filtered and concen-
trated under reduced pressure, yielding to 8 with 100% conver-
sion. Further purification was carried out by column chromatog-
raphy, starting with 100% petroleum ether, followed by 15%
EtOAc in petroleum ether, affording 8 in quantitative yield.
1H NMR (500 MHz, chloroform-d) δH 7.84 (d, J = 8.6 Hz, 2H),
7.02 (d, J = 8.6 Hz, 2H), 3.91 (s, 3H), 2.02 (t, J = 18.3 Hz, 3H);
19F NMR (471 MHz, chloroform-d) δF −97.3 (s); 13C NMR
(126 MHz, chloroform-d) δC 165.2, 133.1, 122.9, 114.7, 55.8,
16.6 (t, J = 22.2 Hz); HMRS (ESI) m/z: [M + H]+ calcd for
C9H11F2O3S, 236.0310; found, 236.0390; [M + Na]+ calcd,
259.0211; found, 259.0216.
2–(α,α-Difluoroethyl)sulfinyl)naphthalene (11)
(1,1-Difluoroethyl)(naphthalene-2-yl)sulfane (5, 5 mg,
0.022 mmol) was added to a round bottom flask with a stirring
bar and dissolved in a mixture of DCM (3 mL) and methanol
(0.3 mL). The solution was stirred at room temperature until
homogenisation (5 min). AlCl3 (1.5 mg, 0.011 mmol) was
added, and the solution stirred for 5 min, prior to the addition of
[bis(acetoxy)iodo]benzene (BAIB, 11.1 mg, 0.022 mmol). The
reaction was left to stir overnight. After 16 h, the solvents were
evaporated under reduced pressure. Further purification was
achieved by reversed-phase HPLC in a Phenomenex Luna SP
column, with 60:40 AcCN/water (supplemented with 0.05%
TFA) at a flow rate of 1 mL/min, which afforded 11 in 30%
yield. The product 11 was isolated at tR = 37 min, which was
consistent with the metabolic experiments’ data. 1H NMR
(500 MHz, chloroform-d) δH 8.28 (s, 1H), 8.01 (d, J = 8.7 Hz,
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1H), 7.99–7.92 (m, 2H), 7.69 (ddt, J = 8.7, 2.6, 1.3 Hz, 1H),
7.67–7.60 (m, 2H), 1.77 (t, J = 18.5 Hz, 3H); 19F NMR
(471 MHz, chloroform-d) δF −92.9 (d, J = 227.0 Hz), −96.0 (d,
J = 227.0 Hz); 13C NMR (126 MHz, chloroform-d) δC 145.9
(C-Ar, visible in HMBC), 135.1 (s, C-Ar), 133.6 (t, J =
218.8 Hz, CF2), 129.3 (s, C-Ar), 128.8 (s, C-Ar), 128.5 (s,
C-Ar), 128.1 (s, C-Ar), 127.5 (s, C-Ar), 126.8 (s, C-Ar), 121.0
(s, C-Ar), 111.7 (C-Ar, visible in HMBC), 16.5 (t, J = 22.1 Hz,
CF2CH3); HRMS (ESI+) m/z: [M + H]+ calcd for C12H11OF2S,
241.0420; found, 241.0491.
Biotransformations and extraction conditions
Culture media was purchased from Sigma-Aldrich. Each
thioether (5–10 mg) was dissolved in DMF (50 µL) and inocu-
lated into cultures of C. elegans. The cultures were incubated at
28 °C and 180 rpm for 72 h. Blank experiments were carried
out in the absence of C. elegans. After 72 h, the fungal biomass
was removed and washed with diethyl ether. The supernatant
was extracted into diethyl ether (3 × 50 mL) and dichloro-
methane (3 × 50 mL), and the combined organic extracts were
dried over anhydrous Na2SO4, filtered and evaporated under
reduced pressure. The extracts were analysed by 1H and
19F NMR before further purification by HPLC.
Purification of the fluorometabolites
The fluorometabolites (sulfoxides and sulfones) were isolated
by reversed-phase HPLC using a Shimadzu Prominence (SIL-
20A HT autosampler, CL-20AT ternary pump, DGU-20A3R
solvent degasser, SPD 20A UV detector and CVM-20A
controller module), equipped with a Phenomenex semi-prepara-
tive Luna C18 column. Purification of the metabolites was
carried out by HPLC, using an eluent system of 60:40 AcCN/
water (both supplemented with 0.05% TFA), at a flow rate of
1 mL/min. For this, the extracts were redissolved in AcCN
(1 mL, HPLC grade), and injected in 10–20 µL batches. Each
fluorometabolite was separated in vials, evaporated and
analysed.
Structural analysis of the resulting metabolites and remaining
starting materials was carried out by NMR characterisation (1H,
19F, 13C, COSY, HSQC and HMBC) and accurate mass spec-
trometry. 19F{1H} and 13C{1H}) NMR spectra were recorded
on Bruker Avance III 500 or Bruker Avance III 500 HD spec-
trometers (500 MHz 1H, 476 MHz 19F, 126 MHz 13C). High-
resolution mass spectrometry was acquired using electrospray
ionisation (ESI), on a ThermoFisher Excalibur Orbitrap Spec-
trometer, operating in positive and negative mode, from solu-
tions of the analyte in methanol or acetonitrile.
The X-ray structure analysis of 7 (CCDC deposition code
1911894) was obtained using a Rigaku XtaLAB P200 diffrac-
tometer, using multi-layer mirror monochromed Mo Kα radia-
tion.
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